Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Outline of Final Research Achievements |
Through bioinformatic analysis and functional genomics of refractory endometrial cancer subtypes, STAT1 pathway in serous carcinoma as well as GPR54-metastin axis in low grade endometrioid adenocarcinoma were detected as key molecules of tumor progression and new potent therapeutic targets. Based on these findings, development of molecular targeting therapy are in preparation as several international cooperative researches.
|